Caris Life Sciences Reports Record Q3 2026 Results and Raises Full-Year Revenue Guidance
Caris Life Sciences (CAI) reported record third-quarter results for 2026, highlighted by a 27% year-over-year revenue increase to $275.4 million. Growth was primarily driven by a 21% surge in clinical volume, reaching 61,500 cases, and improvements in average selling prices (ASP). The company also achieved GAAP profitability this quarter, reporting a net income of $15.3 million. Following these strong results, management raised its full-year revenue guidance to a range of $1.04 billion to $1.05 billion. While operating expenses rose to $163 million due to commercial expansion and marketing for the Caris Detect platform, the company maintains a strong liquidity position with $769.2 million in cash and investments to fund future R&D and product pipeline initiatives.
Tickers: $CAI
Topics: guidance upgrade molecular profiling profitability revenue growth